Affimed to Host Research & Development Day on Friday, December 7, 2018 in New York City

Date : 11/28/2018 @ 5:00AM
Source : GlobeNewswire Inc.
Stock : Affimed NV (AFMD)
Quote : 2.28  -0.03 (-1.30%) @ 12:59AM
After Hours
Last Trade
Last $ 2.28 ◊ 0.00 (0.00%)

Affimed to Host Research & Development Day on Friday, December 7, 2018 in New York City

Affimed NV (NASDAQ:AFMD)
Historical Stock Chart

2 Years : From Dec 2017 to Dec 2019

Click Here for more Affimed NV Charts.

Heidelberg, Germany, November 28, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate and adaptive immunity (NK cells, macrophages and T cells), today announced that it will host a Research & Development Day on Friday, December 7, 2018 from 8:30 am to 11:30 am ET in New York City.

In addition to presentations on the Company’s clinical development strategy for its lead product candidate AFM13 and its advanced innate immune cell engager pipeline, the event will feature guest speakers Dr. Steven M. Horwitz, Associate Attending, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, Dr. Yago Nieto, Professor of Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, and Dr. Ahmed Sawas, Assistant Professor of Medicine, Columbia University College of Physicians and Surgeons and the New York-Presbyterian Hospital. The speakers have extensive background in the development of innovative medicines in hematological malignancies including T cell lymphoma and Hodgkin lymphoma.

A live webcast of the full program can be accessed through the “Events” section on the “Investors & Media” page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed’s website for 30 days following the event.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK cells, macrophages and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.

Affimed Media Contact:Anca Alexandru, Head of Communications, EU IRE-Mail: media@affimed.com

Affimed Investor Contact:Gregory Gin, Head of Investor RelationsE-Mail: IR@affimed.com

 

Latest AFMD Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.